All News
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
ARD's Impact Factor
EULAR
Annals of the Rheumatic Diseases (ARD) is the official journal of EULAR –The European Alliance of Associations for Rheumatology. An international peer-reviewed publication committed to promoting the highest standards of scientific exchange and education.
GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions and discusses their potential implications for clinical practice and research, especially for the increasingly perplexed rheumatologist.
Read Article
Rheumatoid Arthritis Panel: EULAR 2025
Panelists Drs. Mrinalini Dey, Janet Pope, Jonathan Kay and Jack Cush review RA studies and sessions presented at the 2025 EULAR meeting in Barcelona, Spain. Abstracts discussed: OP0004; OP0105; LB0006; OP0327; OP0330; OP0232; 0P0190. https://t.co/hmosUKOgTt
Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitors - Long-term Extensions and Uveitis
Dr. Peter Nash offers his perspective on data presented at the 2025 EULAR meeting in Barcelona.
https://t.co/eQd0TcQn76 https://t.co/6Zog4LC8Aj
Links:
Dr. John Cush RheumNow ( View Tweet)
There's an App for That (and it works): the AXIA RCT
Dr. Aurelie Najm reports on abstract LB0002 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/IRZ1L7BqLW https://t.co/Av2vVheShE
Links:
Dr. John Cush RheumNow ( View Tweet)
Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases
During the Late-Breaking Abstract session at EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD).
https://t.co/5bjyaqTqSN https://t.co/i4mGMYfyNK
Dr. John Cush RheumNow ( View Tweet)
National Psoriasis Found. Consensus Defines On-Treatment Remission in Plaque Psoriasis as 0% BSA and MD global=0 for at least 6 months while on treatment. For both clinical practice and clinical trials. https://t.co/QJg0ZIQ5Mv https://t.co/0FnbFcpXQB
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – RA Panel Discussion
Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care. https://t.co/hoxz0zWieN
Dr. John Cush RheumNow ( View Tweet)
Eular 2025 PsA Topic Panel
https://t.co/wJ08aKGZfJ https://t.co/6OvkIeOT76
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – SpA Panel Discussion
Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.
https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6
Dr. John Cush RheumNow ( View Tweet)
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/cZCgoRHbDZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Why is RA Difficult to Treat?
Dr. Jonathan Kay shares his perspective on five posters presented at EULAR 2025 in Barcelona, Spain. Posters reviewed: POS0027, POS0028, POS0185, POS0030, POS0163
https://t.co/Ad4hVN21MJ https://t.co/d0BfQWjjL0
Dr. John Cush RheumNow ( View Tweet)
Difficult to Treat Psoriatic Arthritis
Dr. Eric Ruderman shares his perspectives on data being presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/AdKILLc12Y https://t.co/4pB0OH2Gup
Dr. John Cush RheumNow ( View Tweet)
Does Abatacept Buy You Time Off RA?
Dr. David Liew reports on abstract OP0325 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/t8NLvPjcju https://t.co/bloTKQ87rv
Dr. John Cush RheumNow ( View Tweet)
Social Determinants of Health in SLE
Dr. Mrinalini Dey interviews Dr. Elena Nikiphorou about the topic of social determinants of health in systemic lupus erythematosus, and data being presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/gSFIV8uIuE https://t.co/VpqzVRSwh9
Dr. John Cush RheumNow ( View Tweet)
Predicting Psoriatic Arthritis in Psoriasis: How Close Are We?
Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies https://t.co/RLz1FoQxvc
Dr. John Cush RheumNow ( View Tweet)
Nurse-Led Treat-to-Target Clinics
New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.
https://t.co/sV8IHhnwbm https://t.co/IrJKvceyez
Dr. John Cush RheumNow ( View Tweet)
How to properly use steroids in early RA
Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. https://t.co/FakKxRot0p
Dr. John Cush RheumNow ( View Tweet)
2025 update of EULAR recommendations on lupus nephritis
At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented updated EULAR recommendations on managing lupus nephritis (LN). The key change is that the historic standard of care (mycophenolate with https://t.co/K3s1RIpEES
Dr. John Cush RheumNow ( View Tweet)
